Pfizer presents the opening keynote at the SMi’s ADC Conference 2018

SMi’s global panel of speakers will strengthen your knowledge in key topics such as high potent ingredients, ADC payloads, PK-PD technological advancements, warheads and site selectivity, immune-oncological combination therapies and fragment drug conjugates.

Industry News:

Pfizer received FDA approval for Mylotarg™ (Gemtuzumab Ozogamicin), in 2000 the only approved antibody-drug conjugate for newly diagnosed and relapsed or refractory CD33-positive acute myeloid leukemia. It has been recently announced that earlier this year, Pfizer resubmitted a biologics license application (BLA) for Mylotarg™ on June 11, 2017. The firm announced the FDA's Oncologic Drug Advisory Committee (ODAC) voted that clinical results demonstrated a favourable beneficial risk for the drug. http://bit.ly/2hOSpE1

Another anitobody-drug conjugate which was also approved earlier this year is, Besponsa (Inotuzumab Ozogamicin). Beponsa is an ADC comprised of a monoclonal antibody (mAb) targeting CD22, a cell surface antigen expressed on cancer cells, linked to a cytotoxic agent. The approval is based on the results of the phase III INO-VATE acute lymphoblastic leukemia (ALL) trial involving 326 patients with relapsed or refractory ALL, which showed that inotuzumab outperformed current standards of care. http://bit.ly/2zeQr6L

Pfizer is using its understanding of the biology of cancer to explore a number of antibody-linker-cytotoxin combinations and build proprietary ADC platforms, to develop a diverse ADC toolkit.

Event Spotlight:

Hear more from Pfizer in an opening key note address on new advancements in next-generation ADC development when SMi welcome the expertise of Alison Betts, ADC Scientist next April.

With a focus on modelling and simulation, Alison will provide attendees with exclusive insight sorrounding key developments in Kadcyla, a HER-2 ADC approved in 2013; PK/PD methodologies for efficacy and safety differentiation; and a proposed mechanistic target mediated drug disposition model.

For those looking to attend there is currently a £400 early-bird saving, ending December 15th

Further information is available at: www.adcsummit.com/phpr

SMi presents the 6th Annual Conference:

ADC Summit
Date: 9th – 10th April 2018
Location: Copthorne Tara Hotel, London UK
Website: www.adcsummit.com/phpr

---end---

Contact Information:

For all media inquiries contact Pavan Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk